Royalty Pharma plc (RPRX) Prices 17.34M Class A Share Secondary Offering at $42/Sh by Selling Shareholders

Royalty Pharma plc (NASDAQ: RPRX) announced today the pricing of the secondary offering of 17,343,037 shares of its Class A ordinary shares by selling shareholders in an underwritten public offering pursuant to a registration statement on Form S-1 filed with the U.S. Securities and Exchange Commission (“SEC”) at a price to the public of $42.00 per share. The selling shareholders have granted the underwriters an option to purchase up to 2,601,455 additional Class A ordinary shares. The Company will not receive any of the proceeds from the sale of its Class A ordinary shares by the selling shareholders. The offering is expected to close on October 20, 2020, subject to customary closing conditions.

J.P. Morgan, Morgan Stanley, BofA Securities, Goldman Sachs & Co. LLC and Citigroup are acting as joint lead book-running managers and as representatives of the underwriters for the proposed offering. Cowen, Evercore ISI, Truist Securities and UBS Investment Bank are also acting as joint book-running managers for the offering. BBVA, DNB Markets, Scotiabank, TD Securities, Academy Securities, AmeriVet Securities, Blaylock Van, LLC, Cabrera Capital Markets LLC, R. Seelaus & Co., LLC, Ramirez & Co., Inc., Siebert Williams Shank and Tigress Financial Partners are acting as co-managers for the offering.

This offering is being made only by means of a prospectus.

You May Also Be Interested In

• Fisker (FSR) files form 10-K, sees more job cuts, reiterates going concern doubts
• Pioneer Power (PPSI) Receives Nasdaq Non-compliance Notice
• Cyngn Inc (CYN) Announces Pricing of $5.0 Million Firm Commitment Public Offering of Common Stock